Use of gefitinib ('Iressa', ZD1839) in advanced non-small-cell lung cancer for routine clinical practice

被引：0
|
作者：
Bendel, J [1 ]
Häusler, J [1 ]
Korfee, S [1 ]
Antoch, G [1 ]
Gauler, T [1 ]
Eberhardt, W [1 ]
机构：
[1] Univ Hosp Essen, Essen, Germany
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [21] Activity of the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in refractory non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Zucali, P
    Campagnoli, E
    Latteri, F
    Biancofiore, G
    Abbadessa, G
    Morenghi, E
    Santoro, A
    BRITISH JOURNAL OF CANCER, 2003, 89 : S33 - S33
  • [22] Gefitinib ('Iressa', ZD1839) in patients with brain metastases from non-small-cell lung cancer:: report of four cases
    Cappuzzo, F
    Ardizzoni, A
    Soto-Parra, H
    Gridelli, C
    Maione, P
    Tisea, M
    Calandri, C
    Bartolini, S
    Santoro, A
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [23] Gefitinib ('Iressa', ZD1839) in patients with brain metastases from non-small-cell lung cancer:: report of four cases
    Cappuzzo, F
    Calandri, C
    Bartolini, S
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [24] Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    Santoro, A
    Cavina, R
    Latteri, F
    Zucali, PA
    Ginanni, V
    Campagnoli, E
    Ferrari, B
    Morenghi, E
    Pedicini, V
    Roncalli, A
    Alloisio, M
    Ravasi, G
    Parral, HJS
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 33 - 37
  • [25] Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study
    Dongiovanni, Vincenzo
    Dongiovanni, Diego
    Buffoni, Lucio
    Barone, Carla
    Fissore, Camilla
    Addeo, Alfredo
    Larovere, Erika
    Grillo, Raffaella
    Nuzzolo, Gloria
    Schena, Marina
    Bertetto, Oscar
    ANNALS OF ONCOLOGY, 2005, 16 : 21 - 22
  • [26] Quality-of-life benefits for a patient with non-small-cell lung cancer and brain metastases taking gefitinib ('Iressa', ZD1839)
    van Zandwijk, N
    BRITISH JOURNAL OF CANCER, 2003, 89 : S34 - S34
  • [27] Analysis of the efficacy and tolerability of gefitinib ('Iressa', ZD1839) in previously treated patients with non-small-cell lung cancer enrolled in the 'Iressa' Expanded Access Programme
    de Leeuw, K
    Schallier, D
    Sermijn, E
    Fontaine, C
    Neyns, B
    Samijn, I
    de Grève, J
    BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [28] Gefitinib ('Iressa', ZD1839) in heavily pretreated non-small-cell lung cancer patients: a case series report from the 'Iressa' Expanded Access Programme
    Gridelli, C
    Rossi, A
    Maione, P
    Musto, L
    Del Gaizo, F
    Airoma, G
    BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
  • [29] Refractory non-small-cell lung cancer: clinical experience with gefitinib ('Iressa', ZD1839) in 28 patients who entered the 'Iressa' Expanded Access Programme at the Sydney Cancer Centre
    Boyer, M
    BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [30] Gefitinib ('IRESSA', ZD1839) in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience
    Maisey, NR
    Parton, M
    Harper-Wynne, C
    Sumpter, K
    Ashley, S
    Eisen, T
    O'Brien, M
    BRITISH JOURNAL OF CANCER, 2004, 91 : S15 - S15
12345